Esprit BTK Everolimus Eluting Resorbable Scaffold System
ABBOTT MEDICAL · Decision date Apr 26, 2024
What did the FDA approve?
The FDA approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System from Abbott Medical on April 26, 2024. The approval covers improving luminal diameter in infrapopliteal lesions for patients with Chronic Limb Threatening Ischemia, where total scaffolding length reaches up to 170 mm and reference vessel diameter is between 2.5 mm and 4.00 mm.
The device is classified as an absorbable infrapopliteal scaffold under product code NXW in the cardiovascular specialty. The approval statement describes the indicated use but does not provide independent evidence of safety or clinical effectiveness. No supplement type or reason is listed, so the record does not indicate whether this is an original PMA or a change to a prior approval.
FDA approval order statement
The Esprit BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with Chronic Limb Threatening Ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of >= 2.5 mm and <= 4.00 mm.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 26, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230036
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- NXW
- Decision code
- APPR
- Decision date
- Apr 26, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Scaffold, infrapopliteal, absorbable.
- Applicant
- Abbott Medical
- Product code
- NXW
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230036 received
Application receipt date recorded by FDA.
P230036 · FDA decision
APPR
P230036/S020 · Related supplement
Esprit BTK Everolimus Eluting Resorbable Scaffold System
Timeline entries are records held by MedtechLedger for P230036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Sep 24, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 3200 Lakeside Dr., Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P230036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records